ERBB2 and breast carcinoma: Our results demonstrate that endocrine therapy with letrozole, in addition to standard neoadjuvant chemotherapy, is well tolerated, but does not provide a higher pathologic response rate in early HR-positive, HER2-negative breast cancer.